Atlas Trials

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Clinical trial NCT01590459 · COMPLETED

Trial details

NCT number
NCT01590459
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2012-04-01
Primary completion
2014-07-01
Enrollment
359

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.